According to the packet definition, the disease involves misfolding of monoclonal immunoglobulin light chains, usually produced by a plasma cell tumor, with deposition of the resulting amyloid fibrils. The packet lists no known genes and no inheritance patterns, so no genetic cause or inheritance pattern is described.

No diagnostic methods, GeneReviews diagnosis content, or newborn screening information are certified in this packet. How AL amyloidosis is diagnosed is therefore not described here.

The packet contains no certified FDA approval records, so FDA-approved options are unknown in this packet. Orphan-drug records list Darzalex Faspro (daratumumab and hyaluronidase-fihj, Janssen) with status approved for light-chain (AL) amyloidosis. Orphan designation, which is not approval, is recorded for birtamimab (Prothena) and for N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide (ProtaMed). Three further orphan designations are recorded as withdrawn. No foundational therapies or GeneReviews management content are certified. Patient assistance programs may exist for some therapies; none are certified in this packet.

Natural history and prognosis are not certified in this packet, so no statement about outcomes is made here.

The packet reports 60 ClinicalTrials.gov records for AL amyloidosis, all counted as active. Examples include NCT05898646, a Phase 2 daratumumab maintenance study sponsored by Mayo Clinic (recruiting; 2023-09-06 to 2031-11-30); NCT05451771, a Phase 1 venetoclax-dexamethasone study in relapsed or refractory t(11;14) amyloidosis sponsored by Columbia University (active, not recruiting; 2022-10-26 to 2027-09-01); NCT06569147, a Phase 1 elranatamab study sponsored by Dana-Farber Cancer Institute (recruiting; 2024-11-01 to 2029-07-01); and NCT05145816, a Phase 1/2a belantamab mafodotin study sponsored by the University of Texas Southwestern Medical Center (recruiting; 2024-02-15 to 2027-09-01). The packet's publication digest classifies 285 papers, with reviews and meta-analyses the dominant type. Trial statuses are as recorded in the packet and may have changed.